Attorneys at Sheppard Mullin published an analysis on August 27, 2026, examining the Pharmacy Compounding Advisory Committee’s July 2026 votes recommending six peptides for inclusion on the 503A Bulks List. The analysis emphasizes that PCAC recommendations are advisory only and that the FDA is not legally required to adopt them.
The six peptides at issue are BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. While the advisory committee’s votes drew significant attention across the compounding and telehealth sectors, Sheppard Mullin’s analysis makes clear that no law changed as a result of the meeting. The firm projects that formal notice-and-comment rulemaking to include or exclude these peptides from the 503A Bulks List will likely extend into 2027 or 2028.
The analysis also highlights FDA’s core scientific objection to these peptides: the agency has noted a lack of sufficiently defined quality standards. This concern could factor into any subsequent rulemaking process, though the analysis does not specify how the agency will ultimately address it.
What happened
In July 2026, the Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six peptides for the 503A Bulks List, which governs which bulk drug substances can be used by traditional compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act. On August 27, 2026, Sheppard Mullin attorneys published a legal analysis of those votes, concluding that the recommendations are nonbinding and that the FDA retains full discretion over whether to act on them.
According to the firm, any actual legal change—whether inclusion or exclusion of these peptides on the 503A Bulks List—would require a formal notice-and-comment rulemaking process. Sheppard Mullin projects that this process will likely extend into 2027 or 2028 before any final rule takes effect.
Why it matters
The timeline confirmation has significant implications for compounding pharmacies, telehealth platforms, peptide manufacturers, and consumers. For 503A compounding pharmacies, beginning to compound BPC-157, KPV, TB-500, MOTS-c, Epitalon, or Semax before final rulemaking carries enforcement risk, because the advisory votes did not alter the legal status of these substances.
For telehealth peptide prescribers, the analysis reinforces that the PCAC votes changed no law and that prescribing decisions remain subject to existing regulatory constraints. For manufacturers, FDA’s stated concern about the absence of defined quality standards represents a potential hurdle that could factor into any future rulemaking. For consumers, the analysis confirms that no legal access change has occurred and that any change is likely years away.
What to watch next
- Whether the FDA initiates formal notice-and-comment rulemaking on any of the six peptides.
- How the agency addresses its stated concern about the lack of defined quality standards for these peptides.
- Whether compounding pharmacies or telehealth platforms attempt early adoption despite the enforcement risk outlined in the analysis.
- Any additional PCAC meetings or FDA communications regarding the 503A Bulks List timeline.
Sources
Sheppard Mullin — Compounded Peptides on the Loose: What the Recent PCAC Meeting Means for Industry
Industry information only. Not medical or legal advice.
